C. R. Bard, Inc., now branded as Bard, headquartered in Murray Hill, New Jersey, USA, was a developer, manufacturer, and marketer of medical technologies in the fields of vascular, urology, oncology, and surgical specialties before its acquisition by BD. In April 2017, the company has announced that it will be acquired by Becton Dickinson. The transaction was completed later that year.